Human Services Committee
Extreme Cost Drugs

• January 11, 2022
• Brendan Joyce, PharmD
History

• Omnibus Budget Reconciliation Act of 1990 created the modern Medicaid prescription drug program
  • Medicaid Drug Rebate Program
  • Covered Outpatient Drug definition

• State Medicaid prescription drug programs
  • Required to cover FDA approved drugs for all manufacturers who have a signed Medicaid drug rebate agreement
  • Doesn’t matter if drug is orphan drug designation, accelerated approval, biologic, or otherwise; if it is approved by the FDA, Medicaid must pay
History – things have changed since OBRA ‘90
History – things have changed since OBRA ‘90
Extreme Cost Drugs

• There is no definition or actual category
• Any attempt to categorize tends to need adjustment quickly
• 1991 most expensive drug was $150,000 a year (Ceredase)
• 2010 $400,000 a year (Soliris)
• 2018 $624,000 a year (Actimmune)
• 2021 ND Medicaid paid $2.125 million for one drug claim (Zolgensma)
Current Extreme Cost Drugs

• 7 patients on CF drugs (6 @ $24,000 a month, 1 @ $21,000 a month)
  • $1.98 million per year
• 11 patients on high cost chemotherapy (all > $13,000 a month)
  • $2.25 million annualized
• 5 patients on seizure drugs ($9,000 to $52,500 a month)
  • $1.6 million per year
• Others at $15,000 per month, $16,000 every 2 weeks, etc.
• New the past few weeks – patient on drug at $31,900 a month
• Nothing is surprising anymore
Volume of claims > $1000 (traditional Medicaid through most of November 2021)
Spend on Claims > $1000

Amount Paid

Increasing Proportion of Pharmacy Spend

% of Spend from Rx's > $1000
FDA Approval

• Prior to 1991, FDA approval only given if proven safe and effective
• With accelerated approval pathway in 1991, effectiveness no longer needed to be proven
  • Instead used surrogate endpoints that may hopefully predict that the drug will impact the disease in a positive way
  • Used for completely new drugs or new indications for existing drugs
• Lack of any proven efficacy hasn’t decreased demand from prescribers and families
FDA Approval – Accelerated Applications

• 40 approved 1992-1999 (2 haven’t completed studies, 3 withdrawn)
• 61 approved 2000-2009 (2 haven’t completed studies, 14 withdrawn)
• 93 approved 2010-2018 (41 haven’t completed studies, 4 withdrawn)
• 75 approved 2019-June 2021 (1 withdrawn, 3 fully approved)
• Overall
  • 22 have been withdrawn (8.2%)
  • 116 have not completed required studies for full approval (43.1%)
    • Includes those whose follow-up studies have proven the medication is NOT effective for that indication but the FDA hasn’t forced market withdrawal
  • 131 have received traditional approval after completing studies (48.7%)
Medicaid covers Accelerated Approval Drugs

- Many cancer drugs
  - Keytruda accounts for 34 (12.6%) of all accelerated approvals
  - One Keytruda application since withdrawn and 6 converted to full approval
- Makena (prevent premature birth – has been proven to not be effective but FDA has not removed it from the market)
- Exondys (Duchenne Muscular Dystrophy)
- Aduhelm (Alzheimer’s)
- Other FDA approval options include Fast Track, Breakthrough, Priority Review, Orphan drug
  - Zolgensma, the $2.125 million drug for spinal muscular atrophy is all of these
Logic and Reason not being followed

• Medicaid is not reimbursed for all past expenditures if a drug is found to not be effective and then withdrawn (and sometimes NOT withdrawn)
  • Can only recoup if manufacturer is found to have obtained original accelerated approval through fraudulent means

• Value Based Purchasing – little incentive for manufacturers to come to a deal that results in less revenue for them

• Medications that (hopefully) stop disease progression are priced the same regardless of the patient’s current disease progression

• Weight based medication pricing penalizes states for having an outlier

• Difficult for states to budget based on genetic prevalence

• Drug originally priced for small population doesn’t adjust when population increases due to new or expanded indications
Humira – ever expanding indications

$1,178/Rx in 2003; $6,800/Rx in 2020 (min $5,400, max $16,680)
Risk

• Small budget states can be significantly impacted
  • One drug claim increased ND Medicaid’s medical drug expenditures 84% quarter over quarter

• Genetic based diseases have higher prevalence in places where there are higher populations of those who are genetically predisposed

• Diseases with higher prevalence in colder climates cause northern tier states to be disproportionately affected
  • Copaxone for Multiple Sclerosis
    • $803/month in 2000
    • $7,114/month in 2020
Solutions

• Congress
  • Centralize payment to minimize variability of risk to states
    • If there are only 100 people in the nation who have a genetic disease, and 20/100 live in ND because it happens most often in those of Scandinavian/German descent, ND shouldn’t have to absorb those costs into their budget
  • Give FDA explicit authority and direction to remove medications from the market if they are proven ineffective
  • Remove approvals and force reimbursement for all payments if confirmatory trials are not completed timely
  • Force increased rebates when indications have expanded

• North Dakota
  • Ensure Medicaid has the flexibility to react quickly
How is ND Medicaid doing overall

• DHS works hard to be a leader in claim payment methodology leveraging Prospective Drug Use Review edits to ensure the best possible pharmaceutical care for our members

• If ND pharmacy growth matched National Health Expenditure (NHE) Medicaid pharmacy growth percentages historically since 1999, our net spend would have been $23.6 million higher for 2020*
  • *Understated as 2020 NHE growth rates not yet released so 0% growth was used
Pharmacy Growth NHE vs ND Medicaid
After Part D

• Part D started in 2006
  • ND’s drop in expenditures was larger than NHE due to high % of aged in ND and continuing program improvements

• 2007 through 2013, ND outperformed NHE % growth overall
  • $100 script in 2006 would have inflated to $110.54 vs $94.85 for ND Medicaid

<table>
<thead>
<tr>
<th>Year</th>
<th>NHE % Growth</th>
<th>ND % Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>-4.0%</td>
<td>-7.6%</td>
</tr>
<tr>
<td>2008</td>
<td>4.9%</td>
<td>1.1%</td>
</tr>
<tr>
<td>2009</td>
<td>5.8%</td>
<td>-4.8%</td>
</tr>
<tr>
<td>2010</td>
<td>0.3%</td>
<td>0.8%</td>
</tr>
<tr>
<td>2011</td>
<td>1.8%</td>
<td>7.6%</td>
</tr>
<tr>
<td>2012</td>
<td>1.0%</td>
<td>-1.4%</td>
</tr>
<tr>
<td>2013</td>
<td>0.6%</td>
<td>-0.3%</td>
</tr>
</tbody>
</table>
Medicaid is Unique

• Federal law governs drug coverage
• Federal law governs drug rebates
• Rebate percent of spend was 21.5% in 2001 and 33.9% in 2007
• Rebate percent of spend was 72.1% in 2020
• Net spend traditional Medicaid 2007 (average 50,002 recipients)
  • $18.7 million
• Net spend traditional Medicaid 2020 (average 74,241 recipients)
  • $11.5 million
Medicaid is Unique – 19 classes Expansion
Final Thoughts

• Extreme cost drugs will continue to increase in volume and costs
• Congress likely won’t provide solutions
• Specialized staff and ability to manage the program (including system changes), and the legislative support for such, has led to ND Medicaid outperforming NHE growth
• ND Medicaid needs to continue to have the flexibility to react as needed

• Questions?